NLR family CARD domain containing 5 promotes hypoxia-induced cancer progress and carboplatin resistance by activating PI3K/AKT via carcinoembryonic antigen related cell adhesion molecule 1 in non-small cell lung cancer

References

• Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–454.
   PubMed Web of Science ®Google Scholar
• Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133–150.
   PubMed Web of Science ®Google Scholar
• Nikfarjam S, Rezaie J, Kashanchi F, et al. Dexosomes as a cell-free vaccine for cancer immunotherapy. J Exp Clin Cancer Res. 2020;39(1):258.
   PubMed Web of Science ®Google Scholar
• Rossi A, Di Maio M. Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles. Expert Rev Anticancer Ther. 2016;16(6):653–660.
   PubMed Web of Science ®Google Scholar
• Kim C, Giaccone G. Precision oncology in non-small-cell lung cancer: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(6):348–349.
   PubMed Web of Science ®Google Scholar
• Jabbari N, Nawaz M, Rezaie J. Bystander effects of ionizing radiation: conditioned media from X-ray irradiated MCF-7 cells increases the angiogenic ability of endothelial cells. Cell Commun Signaling. 2019;17(1):165.
   PubMed Web of Science ®Google Scholar
• Jung Y, Lippard SJ. Direct cellular responses to platinum-induced DNA damage. Chem Rev. 2007;107(5):1387–1407.
   PubMed Web of Science ®Google Scholar
• Mack PC, Gandara DR, Lara PN Jr. Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globalization: the ‘common arm’ approach. Expert Rev Anticancer Ther. 2012;12(12):1591–1596.
   PubMed Web of Science ®Google Scholar
• Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–378.
   PubMed Web of Science ®Google Scholar
• Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007;33(1):9–23.
   PubMed Web of Science ®Google Scholar
• Wang L, Ma L, Xu F, et al. Role of long non-coding RNA in drug resistance in non-small cell lung cancer. Thorac Cancer. 2018;9(7):761–768.
   PubMed Web of Science ®Google Scholar
• DeClerck K, Elble RC. The role of hypoxia and acidosis in promoting metastasis and resistance to chemotherapy. Front Biosci (Landmark edition). 2010;15(1):213–225.
   Google Scholar
• Yang N, Liang Y, Yang P, et al. Propofol suppresses LPS-induced nuclear accumulation of HIF-1α and tumor aggressiveness in non-small cell lung cancer. Oncol Rep. 2017;37(5):2611–2619.
   PubMed Web of Science ®Google Scholar
• Gong T, Cui L, Wang H, et al. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway. J Transl Med. 2018;16(1). DOI:10.1186/s12967-018-1543-2.
   Google Scholar
• Ullah A, Leong SW, Wang J, et al. Cephalomannine inhibits hypoxia-induced cellular function via the suppression of APEX1/HIF-1alpha interaction in lung cancer. Cell Death Dis. 2021;12(5):490.
   PubMed Web of Science ®Google Scholar
• Yao Y, Qian Y. Expression regulation and function of NLRC5. Protein Cell. 2013;4(3):168–175.
   PubMed Web of Science ®Google Scholar
• Rodriguez GM, Bobbala D, Serrano D, et al. NLRC5 elicits antitumor immunity by enhancing processing and presentation of tumor antigens to CD8(+) T lymphocytes. Oncoimmunology. 2016;5(6):e1151593.
   PubMed Web of Science ®Google Scholar
• Ong CEB, Patchett AL, Darby JM, et al. NLRC5 regulates expression of MHC-I and provides a target for anti-tumor immunity in transmissible cancers. J Cancer Res Clin Oncol. 2021;147(7):1973–1991.
   PubMed Web of Science ®Google Scholar
• Peng YY, He YH, Chen C, et al. NLRC5 regulates cell proliferation, migration and invasion in hepatocellular carcinoma by targeting the Wnt/beta-catenin signaling pathway. Cancer Lett. 2016;376(1):10–21.
   PubMed Web of Science ®Google Scholar
• Zong Z, Song Y, Xue Y, et al. Knockdown of LncRNA SCAMP1 suppressed malignant biological behaviours of glioma cells via modulating miR-499a-5p/LMX1A/NLRC5 pathway. J Cell Mol Med. 2019;23(8):5048–5062.
   PubMed Web of Science ®Google Scholar
• Wang Q, Ding H, He Y, et al. NLRC5 mediates cell proliferation, migration, and invasion by regulating the Wnt/beta-catenin signalling pathway in clear cell renal cell carcinoma. Cancer Lett. 2019;444:9–19.
   PubMed Web of Science ®Google Scholar
• Hu X, Wang M, Cao L, et al. miR-4319 suppresses the growth of esophageal squamous cell carcinoma via targeting NLRC5. Curr Mol Pharmacol. 2020;13(2):144–149.
   PubMed Web of Science ®Google Scholar
• Li X, Guo F, Liu Y, et al. NLRC5 expression in tumors and its role as a negative prognostic indicator in stage III non-small-cell lung cancer patients. Oncol Lett. 2015;10(3):1533–1540.
   PubMed Web of Science ®Google Scholar
• Zheng J, Li X, Cai C, et al. MicroRNA-32 and MicroRNA-548a promote the drug sensitivity of non-small cell lung cancer cells to cisplatin by targeting ROBO1 and inhibiting the activation of wnt/beta-catenin axis. Cancer Manag Res. 2021;13:3005–3016.
   PubMed Web of Science ®Google Scholar
• Hong W, Xue M, Jiang J, et al. Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC). J Exp Clin Cancer Res. 2020;39(1):149.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Zhou X, Kang Y, et al. Circ-CCS is identified as a cancer-promoting circRNA in lung cancer partly by regulating the miR-383/E2F7 axis. Life Sci. 2021;267:118955.
   PubMed Web of Science ®Google Scholar
• Xiao M, Liang Z, Yin Z. Long non‑coding RNA ZFPM2‑AS1 promotes colorectal cancer progression by sponging miR‑137 to regulate TRIM24. Mol Med Rep. 2021;23(2):98.
   PubMed Web of Science ®Google Scholar
• Liu C, Xu Y, Liu X, et al. Upregulation of LINC00511 expression by DNA hypomethylation promotes the progression of breast cancer. Gland Surg. 2021;10(4):1418–1430.
   PubMed Web of Science ®Google Scholar
• Zhang ZY, Gao XH, Ma MY, et al. CircRNA_101237 promotes NSCLC progression via the miRNA-490-3p/MAPK1 axis. Sci Rep. 2020;10(1):9024.
   PubMed Web of Science ®Google Scholar
• Pei L, Lv X, Jia G, et al. Silencing circular RNA circ_0054537 and upregulating microRNA-640 suppress malignant progression of renal cell carcinoma via regulating neuronal pentraxin-2 (NPTX2). Bioengineered. 2021;12(1):8279–8295.
   PubMed Web of Science ®Google Scholar
• Fang Z, Chen W, Yuan Z, et al. LncRNA-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation. Biomed Pharmacother. 2018;101:536–542.
   PubMed Web of Science ®Google Scholar
• Li Q, Wang Z, Zhang Y, et al. NLRC5 deficiency protects against acute kidney injury in mice by mediating carcinoembryonic antigen-related cell adhesion molecule 1 signaling. Kidney Int. 2018;94(3):551–566.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Song D, Song Y, et al. Interferon gamma induces inflammatory responses through the interaction of CEACAM1 and PI3K in airway epithelial cells. J Transl Med. 2019;17(1):147.
   PubMedGoogle Scholar
• Han F, Gao Y, Ding CG, et al. Knockdown of NLRC5 attenuates renal I/R injury in vitro through the activation of PI3K/Akt signaling pathway. Biomed Pharmacother. 2018;103:222–227.
   PubMed Web of Science ®Google Scholar
• Zong Y, Zhang Y, Hou D, et al. The lncRNA XIST promotes the progression of breast cancer by sponging miR-125b-5p to modulate NLRC5. Am J Transl Res. 2020;12(7):3501–3511.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang M, Zheng X. High expression of NLRC5 is associated with prognosis of gastric cancer. Open Med. 2018;13(1):443–449.
   Web of Science ®Google Scholar
• Helfrich I, Singer BB. Size matters: the functional role of the CEACAM1 isoform signature and its impact for NK cell-mediated killing in melanoma. Cancers (Basel). 2019;11(3):356.
   PubMed Web of Science ®Google Scholar
• Wicklein D, Otto B, Suling A, et al. CEACAM1 promotes melanoma metastasis and is involved in the regulation of the EMT associated gene network in melanoma cells. Sci Rep. 2018;8(1):11893.
   PubMedGoogle Scholar
• Rayes RF, Vourtzoumis P, Bou Rjeily M, et al. Neutrophil extracellular trap-associated CEACAM1 as a putative therapeutic target to prevent metastatic progression of colon carcinoma. J Immunol. 2020;204(8):2285–2294.
   PubMed Web of Science ®Google Scholar
• Yang C, He P, Liu Y, et al. Down-regulation of CEACAM1 in breast cancer. Acta Biochim Biophys Sin (Shanghai). 2015;47(10):788–794.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Hinoda Y, Takahashi H, et al. Decreased expression of biliary glycoprotein in hepatocellular carcinomas. Int J Cancer. 1997;74(1):15–19.
   PubMed Web of Science ®Google Scholar
• Oliveira-Ferrer L, Tilki D, Ziegeler G, et al. Dual role of carcinoembryonic antigen-related cell adhesion molecule 1 in angiogenesis and invasion of human urinary bladder cancer. Cancer Res. 2004;64(24):8932–8938.
   PubMed Web of Science ®Google Scholar
• Weng CY, Hu XY, Wang YJ. Integrated analysis of gene expression, alteration and clinical significance of carcinoembryonic antigen-related cell adhesion molecule 1 in cancer. 3 Biotech. 2020;10(3):132.
   PubMedGoogle Scholar
• Nolen BM, Lomakin A, Marrangoni A, et al. Urinary protein biomarkers in the early detection of lung cancer. Cancer Prev Res (Phila). 2015;8(2):111–119.
   PubMed Web of Science ®Google Scholar
• Ling Y, Wang J, Wang L, et al. Roles of CEACAM1 in cell communication and signaling of lung cancer and other diseases. Cancer Metastasis Rev. 2015;34(2):347–357.
   PubMed Web of Science ®Google Scholar
• Takeuchi A, Yokoyama S, Nakamori M, et al. Loss of CEACAM1 is associated with poor prognosis and peritoneal dissemination of patients with gastric cancer. Sci Rep. 2019;9(1):12702.
   PubMedGoogle Scholar
• Jiang N, Dai Q, Su X, et al. Role of PI3K/AKT pathway in cancer: the framework of malignant behavior. Mol Biol Rep. 2020;47(6):4587–4629.
   PubMed Web of Science ®Google Scholar
• Lu XX, Cao LY, Chen X, et al. PTEN inhibits cell proliferation, promotes cell apoptosis, and induces cell cycle arrest via downregulating the PI3K/AKT/hTERT pathway in lung adenocarcinoma A549 cells. Biomed Res Int. 2016;2016:2476842.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhou F, Li F, et al. Autocrined leptin promotes proliferation of non-small cell lung cancer (NSCLC) via PI3K/AKT and p53 pathways. Ann Transl Med. 2021;9(7):568.
   PubMed Web of Science ®Google Scholar
• Fan Y, Dong Z, Shi Y, et al. NLRC5 promotes cell migration and invasion by activating the PI3K/AKT signaling pathway in endometrial cancer. J Int Med Res. 2020;48(5):300060520925352.
   PubMed Web of Science ®Google Scholar
• Catalano C, da Silva Filho MI, Jiraskova K, et al. Short article: influence of regulatory NLRC5 variants on colorectal cancer survival and 5-fluorouracil-based chemotherapy. Eur J Gastroenterol Hepatol. 2018;30(8):838–842.
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Yokoyama S, Ieda J, et al. CEACAM1 and hollow spheroid formation modulate the chemosensitivity of colorectal cancer to 5-fluorouracil. Cancer Chemother Pharmacol. 2015;75(2):421–430.
   PubMed Web of Science ®Google Scholar
• Samanta D, Gilkes DM, Chaturvedi P, et al. Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells. Proc Natl Acad Sci U S A. 2014;111(50):E5429–38.
   PubMed Web of Science ®Google Scholar
• Yin X, Liao Y, Xiong W, et al. Hypoxia-induced lncRNA ANRIL promotes cisplatin resistance in retinoblastoma cells through regulating ABCG2 expression. Clin Exp Pharmacol Physiol. 2020;47(6):1049–1057.
   PubMed Web of Science ®Google Scholar
• Liu Z, Liu J, Wei Y, et al. LncRNA MALAT1 prevents the protective effects of miR-125b-5p against acute myocardial infarction through positive regulation of NLRC5. Exp Ther Med. 2020;19(2):990–998.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen Y, Yan Y, et al. Loss of CEACAM1, a tumor-associated factor, attenuates post-infarction cardiac remodeling by inhibiting apoptosis. Sci Rep. 2016;6:21972.
   PubMed Web of Science ®Google Scholar